The Use of Population Pharmacokinetics in Drug Development
- 110 Downloads
Currently, there is an increasing focus on the implementation of pharmacokinetic-pharmacodynamic (PK-PD) studies and modelling as essential tools for drug development. Strategies involving specifically the population approach, which are based on relatively recent statistical methodology (e.g. nonlinear mixed effects modelling, NONMEM) have been advocated for investigating pharmacokinetic and pharmacodynamic variability as well as dose-concentration-effect relationships. The present article outlines this approach, and discusses how it can be implemented within the framework of the studies currently performed as part of the clinical phases of new drug development. It also considers study design and performance, based on real-life experiences.
Population approaches, if designed carefully and early, as part of the planning of the drug development programme, are expected to play a significant role at every phase of the programme and to contribute to providing information that is valuable for registration purposes. Statistical methodology and software are now widely available. However, practical issues such as integration of the population approach within existing protocols, quality control of the data, timing of laboratory and statistical analyses, as well as resource allocation, remain legitimate concerns to be considered in prospective studies.
KeywordsDrug Development Population Approach Tacrine Population Pharmacokinetic Tianeptine
Unable to display preview. Download preview PDF.
- 1.Balant LP, Roseboom H, Gundert-Remy UM. Pharmacokinetic criteria for drug research and development. Adv Drug Res 1990; 19: 1–138Google Scholar
- 3.Peck CC, Harter J, Sanathanan L, et al. Simultaneous pharmacokinetic-pharmacodynamic modeling in drug development and registration. Proceedings of IUPHAR Satellite Symposium on Measurement and kinetics of in vivo drug effects. Noordwijk, The Netherlands: 1990; 28–9Google Scholar
- 8.Sheiner LB. Population approach in drug development: rationale and basic concepts. In: Rowland M, Aarons L, editors. New strategies in drug development and clinical evaluation: the population approach. Luxembourg: Commission of the European Communities, 1992; 13–29Google Scholar
- 9.Gundert-Remy U. Population approach in pharmacokinetics and pharmacodynamics — views within regulatory agencies: Europe. In: Rowland M, Aarons L, editors. New strategies in drug development and clinical evaluation: the population approach. Luxembourg: Commission of the European Communities, 1992; 153–6Google Scholar
- 10.Peck CC. Population approach in pharmacokinetics and pharmacodynamics: FDA view. In: Rowland M, Aarons L, editors. New strategies in drug development and clinical evaluation: the population approach. Luxembourg: Commission of the European Communities 1992; 157–168Google Scholar
- 11.Colburn WA, Olson SC. Classic and population pharmacokinetics. In: Welling PG, Tse FLS, editors. Pharmacokinetics: regulatory, industrial, academic perspectives. New York: Marcel Dekker 1988; 337–84Google Scholar
- 13.Steimer JL, Vozeh S, Racine-Poon A, et al. The population approach: rationale, methods, applications in clinical pharmacology and drug development. In: Welling PE, Balant LP, editors. Handbook of experimental pharmacology. Vol 110: Pharmacokinetics of drugs. Heidelberg: Springer-Verlag, 1994; 405–51Google Scholar
- 15.Rowland M, Aarons L, editors. New strategies in drug development and clinical evaluation: the population approach. Luxembourg: Commission of the European Communities, 1992Google Scholar
- 17.Aarons L, Balant LP, Mentré F, et al. Practical experience and issues in designing and performing population pharmacokinetic/pharmacodynamic studies. Eur J Clin Pharmacol. In pressGoogle Scholar
- 27.Morselli PL. Effect of age on the dose-response curve. In: Lasagna L, Erill S, Naranjo CA, editors. Dose response relationships in clinical pharmacology. New York: Elsevier, 1989; 187–99Google Scholar
- 29.Balant L, Gex-Fabry M, Balant-Gorgia A. The relevance of inter-ethnic differences for drug development and registration: implications for the design and interpretation of phase III clinical trials. In: Walker S, Lumley C, McAuslane N, editors. The relevance of ethnic factors in the clinical evaluation of medicines. London: Kluwer Academic, 1994; 201–17CrossRefGoogle Scholar
- 31.Tanigawara Y, Hori R. Population approach in post-marketing dose adjustment. In: Rowland M, Aarons L, editors. New strategies in drug development and clinical evaluation: the population approach. Luxembourg, Commission of the European Communities 1992; 223–32Google Scholar
- 32.Balant LP. Blood-concentration measurements in clinical trials. Appl Clin Trials 1993; 2: 44–55Google Scholar